Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of GS-6615 in Subjects With Chronic Stable Angina and Coronary Artery Disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eleclazine (Primary)
- Indications Ischaemic heart disorders
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 07 Jun 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 06 Mar 2015 New trial record